Placebo, Vacuna Phleum pratense 3000 TBU/ml, Vacuna Phleum pratense 1000 TBU/ml, Test de provocación nasal Phleum pratense, Vacuna Phleum pratense 6000 TBU/ml
APISLIT-DD-G-2025-01
Phase 2 small_molecule active
Quick answer
Placebo, Vacuna Phleum pratense 3000 TBU/ml, Vacuna Phleum pratense 1000 TBU/ml, Test de provocación nasal Phleum pratense, Vacuna Phleum pratense 6000 TBU/ml for Allergic rhinitis/rhinoconjunctivitis caused by grass polen allergy is a Phase 2 program (small_molecule) at Lacuna Pharma Pty Ltd with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Lacuna Pharma Pty Ltd
- Indication
- Allergic rhinitis/rhinoconjunctivitis caused by grass polen allergy
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active